Champlain Investment Partners LLC Sells 8,647 Shares of Inspire Medical Systems, Inc. $INSP

Key Points

• Champlain Investment Partners LLC reduced its stake in Inspire Medical Systems by 1.9%, now owning 435,762 shares valued at approximately $69.4 million.
• Inspire Medical Systems recently reported earnings of $0.45 per share, surpassing analysts' estimates, and announced a $200 million share repurchase plan, indicating confidence in its stock valuation.
• Analysts have mixed ratings for Inspire Medical Systems, with a consensus rating of "Moderate Buy" and an average price target of $165.62, despite varying target prices from different research firms.

Champlain Investment Partners LLC lessened its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 1.9% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 435,762 shares of the company's stock after selling 8,647 shares during the period. Champlain Investment Partners LLC owned about 1.48% of Inspire Medical Systems worth $69,408,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. True Wealth Design LLC lifted its stake in shares of Inspire Medical Systems by 39.0% in the 4th quarter. True Wealth Design LLC now owns 196 shares of the company's stock worth $36,000 after purchasing an additional 55 shares during the period. Captrust Financial Advisors lifted its stake in shares of Inspire Medical Systems by 2.0% in the 4th quarter. Captrust Financial Advisors now owns 3,034 shares of the company's stock worth $562,000 after purchasing an additional 59 shares during the period. MML Investors Services LLC lifted its stake in shares of Inspire Medical Systems by 0.9% in the 4th quarter. MML Investors Services LLC now owns 7,941 shares of the company's stock worth $1,472,000 after purchasing an additional 67 shares during the period. Mariner LLC lifted its stake in shares of Inspire Medical Systems by 1.6% in the 4th quarter. Mariner LLC now owns 4,837 shares of the company's stock worth $897,000 after purchasing an additional 77 shares during the period. Finally, Allianz Asset Management GmbH lifted its stake in shares of Inspire Medical Systems by 1.6% in the 1st quarter. Allianz Asset Management GmbH now owns 5,000 shares of the company's stock worth $796,000 after purchasing an additional 78 shares during the period. Institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Stock Performance

INSP traded up $2.40 during trading on Monday, reaching $93.86. 656,389 shares of the company traded hands, compared to its average volume of 1,718,609. Inspire Medical Systems, Inc. has a 12-month low of $73.92 and a 12-month high of $225.00. The firm has a fifty day simple moving average of $113.86 and a 200 day simple moving average of $141.01. The company has a market cap of $2.78 billion, a P/E ratio of 54.26, a PEG ratio of 2.92 and a beta of 1.15.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.23. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The business had revenue of $217.09 million during the quarter, compared to analyst estimates of $214.50 million. During the same period last year, the firm posted $0.32 EPS. The company's revenue was up 10.8% on a year-over-year basis. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, sell-side analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Inspire Medical Systems announced that its Board of Directors has initiated a share repurchase plan on Monday, August 11th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to repurchase up to 8.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Truist Financial reiterated a "hold" rating and issued a $125.00 price objective (down previously from $190.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 5th. UBS Group set a $230.00 target price on shares of Inspire Medical Systems and gave the stock a "buy" rating in a report on Tuesday, August 5th. Morgan Stanley reduced their target price on shares of Inspire Medical Systems from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Tuesday, July 15th. KeyCorp lowered shares of Inspire Medical Systems from an "overweight" rating to a "sector weight" rating in a report on Tuesday, August 5th. Finally, Piper Sandler reduced their target price on shares of Inspire Medical Systems from $233.00 to $150.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Inspire Medical Systems currently has a consensus rating of "Moderate Buy" and a consensus target price of $165.62.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.